Related Experiment Video

Updated: Sep 28, 2025

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology
13:17

In Vitro and In Vivo Evaluation of Photocontrolled Biologically Active Compounds - Potential Drug Candidates for Cancer Photopharmacology

Published on: September 29, 2023

2.5K

Discovery of novel photocaged ERK1/2 inhibitors as light-controlled anticancer agents

Rui Chen1, Ziyue Wang1, Lihong Liu1

  • 1State Key Laboratory of Chemical Oncogenomics, Provincial Key Laboratory of Chemical Genomics, School of Chemical Biology and Biotechnology, Shenzhen Graduate School, Peking University Xili University Town, PKU Campus, F-311, Shenzhen, 518055, China. panzy@pkusz.edu.cn.

Chemical Communications (Cambridge, England)
|March 30, 2022
PubMed

Insights

Researchers developed novel photocaged ERK inhibitors for cancer therapy. These compounds are activated by UV light, offering precise treatment with reduced side effects and showing anticancer activity in preclinical models.

Area of Science:

  • Oncology
  • Medicinal Chemistry
  • Photochemistry

Background:

  • Extracellular regulated kinases (ERKs) are crucial targets for cancer treatment.
  • Clinical development of ERK inhibitors is limited by severe side effects.

Purpose of the Study:

  • To develop novel photocaged ERK inhibitors for precise cancer therapy.
  • To evaluate the efficacy and safety of these inhibitors in cancer cell lines and a preclinical model.

Main Methods:

  • Synthesis of a series of photocaged ERK inhibitors.
  • Selective activation of inhibitors using UV irradiation.
  • Assessment of anticancer activity in A375, A549, and HCT116 cancer cell lines.
  • Evaluation of Compound 2 in a zebrafish xenograft model.

Main Results:

  • Photocaged ERK inhibitors were successfully synthesized.
  • Selective UV activation released potent ERK inhibitors.
  • Compound 2 exhibited significant anticancer activity in vitro and in vivo.
  • The approach demonstrated potential for targeted cancer treatment.

Conclusions:

  • Photocaged ERK inhibitors offer a new strategy for precise cancer therapy.
  • UV-activated drug release can mitigate side effects associated with traditional ERK inhibitors.
  • Compound 2 shows promise for further development as a targeted cancer therapeutic.

More Related Videos

An Integrated System to Remotely Trigger Intracellular Signal Transduction by Upconversion Nanoparticle-mediated Kinase Photoactivation11:20

An Integrated System to Remotely Trigger Intracellular Signal Transduction by Upconversion Nanoparticle-mediated Kinase Photoactivation

Published on: August 30, 2017

7.5K
An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model11:04

An In-House-Built and Light-Emitting-Diode-Based Photodynamic Therapy Device for Enhancing Verteporfin Cytotoxicity in a 2D Cell Culture Model

Published on: January 13, 2023

3.2K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.2K